Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
NEW YORK, NY, May 02, 2018 -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Tuesday, May 8th at 12:50pm EDT. Tom LaVoy, CEO of IsoRay, will be presenting as well as meeting with investors.
Tom LaVoy, IsoRay’s CEO, will also be a participant on a panel discussion at 1:45pm EDT entitled “Disruptive Injectables & Oncology”.
The 2018 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.
For those interested in attending, please visit www.DisruptNYC.com for more information.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter@IsoRay.
About RHK Capital:
Advisory Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK Capital is a boutique investment banking firm specializing in small to medium-sized transactions. RHK is led by a management team with extensive financial industry experience and a desire to provide companies and individuals with the tools and expertise to accomplish their financial goals. In addition to investment banking, RHK has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages, and business lending. As a division of Advisory Group Equity Services (AGES), all securities are offered through Advisory Group Equity Services Ltd., a registered broker-dealer, member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.
Contacts: IsoRay Inc. [email protected] (509) 375-1202 Investors: Stephanie Prince, Managing Director PCG Advisory Group [email protected] (646) 762-4518
